Omeros (OMER) Non-Current Assets (2010 - 2026)
Omeros' (OMER) quarterly Non-Current Assets came in at $105.8 million in Q1 2026, down 23.86% year-on-year from $139.0 million in Q1 2025, and down 3.77% quarter-over-quarter from $110.0 million in Q4 2025.
Omeros (OMER) Non-Current Assets (2010 - 2026) Analysis & Trends
Omeros has disclosed Non-Current Assets across 17 years of filings, most recently posting $105.8 million for Q1 2026.
- Non-Current Assets for Q1 2026 came in at $105.8 million, down 23.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $460.6 million (down 21.09% YoY), and the FY2025 annual result was $110.0 million, down 23.08% from the prior year.
- Non-Current Assets came in at $105.8 million for Q1 2026 at Omeros, down from $110.0 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $169.0 million in Q3 2022 to a low of $105.8 million in Q1 2026.
- The 5-year median for Non-Current Assets is $143.1 million (2023), against an average of $142.0 million.
- Across the five-year window, Non-Current Assets jumped 449.14% in 2022 and retreated 23.86% in 2026, its largest moves.
- Omeros' Non-Current Assets stood at $147.7 million in 2022, then advanced by 8.55% to $160.4 million in 2023, then decreased by 10.86% to $143.0 million in 2024, then decreased by 23.08% to $110.0 million in 2025, then declined by 3.77% to $105.8 million in 2026.
- The last three Non-Current Assets figures came in at $105.8 million (Q1 2026), $110.0 million (Q4 2025), and $113.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Omeros | 737.87 Mn | 602.55 Mn | 9.31 Mn | 105.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 105.82 Mn |
| Dec 31, 2025 | 109.97 Mn |
| Sep 30, 2025 | 113.90 Mn |
| Jun 30, 2025 | 130.92 Mn |
| Mar 31, 2025 | 138.98 Mn |
| Dec 31, 2024 | 142.96 Mn |
| Sep 30, 2024 | 148.41 Mn |
| Jun 30, 2024 | 153.38 Mn |
| Mar 31, 2024 | 156.53 Mn |
| Dec 31, 2023 | 160.37 Mn |
| Sep 30, 2023 | 141.73 Mn |
| Jun 30, 2023 | 138.86 Mn |
| Mar 31, 2023 | 143.10 Mn |
| Dec 31, 2022 | 147.73 Mn |
| Sep 30, 2022 | 169.01 Mn |
| Jun 30, 2022 | 152.92 Mn |
| Mar 31, 2022 | 159.04 Mn |
| Dec 31, 2021 | 171.31 Mn |
| Sep 30, 2021 | 32.08 Mn |
| Jun 30, 2021 | 32.99 Mn |